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ABSTRACT
“Radiation recall”—also called “radiation recall der-
matitis”—has been defined as the “recalling” by skin
of previous radiation exposure in response to the ad-
ministration of certain response-inducing drugs. Al-
though the phenomenon is relatively well known in
the medical world, an exact cause has not been docu-
mented. Here, we report a rare occurrence of the ra-
diation recall phenomenon in a breast cancer patient
after palliative radiotherapy for bone, brain, and or-
bital metastases.
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1. HISTORY
A 55-year-old woman was diagnosed with breast
adenocarcinoma in August 2006. In late September,
she complained of back pain and slight numbness. A
bone scan revealed a mild increase in activity in the
thoracic spine and the proximal fourth and anterior
sixth ribs. Magnetic resonance imaging (MRI) of the
spine confirmed metastatic involvement in the tenth
thoracic vertebra. The patient received radiotherapy
with 20 Gy in 5 fractions in October 2006. She toler-
ated the treatment very well with complete pain relief.
The woman returned to her medical oncologist
for systemic therapy. A combination of paclitaxel
(175 mg/m2) and gemcitabine (1000 mg/m2) was
commenced in November 2006. After receiving a
single dose, the patient complained of double vision.
A computed tomography examination confirmed left
orbital metastases (Figure 1) and multiple intraparen-
chymal brain metastases in the left frontal lobe and
left cerebellum. The woman was treated with whole-
brain radiotherapy (WBRT), including the left orbit,
which received a dose of 20 Gy in 5 fractions. The
initial chemotherapy treatment took place 13 days
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before the commencement of the WBRT. No adverse
reactions were observed immediately after the radia-
tion treatment.
Ten days after completion of the WBRT, the pa-
tient received her second dose of paclitaxel and
gemcitabine. Within 2 days, the patient detected
discoloured and inflamed skin limited to the region
that had previously been irradiated. She also experi-
enced swelling in the left ear, muffled hearing, and
discomfort in the eyes as a result of the reaction. Sur-
prisingly, increased pigmentation also occurred in the
area of the thoracic bone metastases treated with pal-
liative radiotherapy approximately 7 weeks earlier.
Silver sulphadiazine cream and hydrocortisone
eardrops were prescribed to treat external symptoms.
All chemotherapy was put on hold.
Approximately 4 weeks after development of the
skin reaction, the patient developed new cervical
nodes compatible with clinical progression of her
breast cancer. Once the external skin reaction had
improved significantly, with only mild discolouration
remaining, chemotherapy was resumed. At this time,
nearly 6 weeks had passed since the appearance of
the radiation recall dermatitis (RRD). A chemotherapy
regimen of cyclophosphamide (600 mg/m2), epi-
rubicin (100 mg/m2), and 5-fluorouracil (600 mg/m2)
replaced the paclitaxel and gemcitabine. Dexametha-
sone (Decadron: Merck, Whitehouse Station, NJ,
U.S.A) was administered at 20 mg before the first
chemotherapy treatment and at 10 mg before each
subsequent treatment. No adverse reactions have oc-
curred since. At follow-up, the patient’s double vi-
sion had improved, and a computed tomography scan
revealed a stable appearance in the orbital metastases.
New MRI examination of the brain, orbits, and spine
revealed no demyelination corresponding to the areas
affected by the RRD reaction.
2. DISCUSSION
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in response to the administration of certain response-
inducing drugs 1. In the medical world, the RRD phe-
nomenon has been termed anything from “moderately
rare” to “moderately common.” No exact cause or
incidence has been documented 2.
D’Angio and colleagues originally documented
RRD in 1959 3; the trigger for the abnormal reaction
was dactinomycin 1. Cytotoxics are common insti-
gators 1. Some medications have been documented
to be more commonly involved with RRD: docetaxel,
doxorubicin, gemcitabine, and paclitaxel (Tables I
and II). Although the association is only a loose one,
Camidge and Price proposed that more-severe skin
reactions are more common when the period be-
tween radiation and the recall-triggering drug is
smaller 1. According to Putnik et al. 60, the median
time between the conclusion of radiation treatment
and the materialization of RRD is 39 days. In the
present case, materialization of the RRD occurred
within 2 days.
Although the precise mechanism of action for RRD
is not known, several mechanisms that may, or may
not, lead to the development of radiation recall have
been proposed. These mechanisms include changes
in vascularization, DNA repair, radiation-impaired
epithelial function of stem cells, and increased sensi-
tivity to drugs 1. Corticosteroids have been suggested
to have some protective effects 61. We found that ste-
roids are commonly used in the treatment of external
symptoms and with the intention of preventing re-
current reactions during subsequent chemotherapy
administration 23,25,26,30,32,33,39,40,43,45,46,50,53,55,59,60.
Most recall reactions have occurred when radio-
therapy and chemotherapy are separated by less than
2 months (Table I). The present case demonstrates a
maximum time frame of 7 weeks separating radia-
tion and resumption of chemotherapy treatment. Of
the total reported cases of RRD outlined here, only
27% (20/75) demonstrated a duration greater than
7 weeks in terms of time passed between completion
of radiotherapy and commencement of chemo-
therapy 1,5–7,12,13,17,19,20,23,24,27,30,37,39,52,53,59.
Although RRD is a rare phenomenon, it poses a
significant barrier to treatment for patients. The con-
dition creates a paradox: patients and clinicians alike
wish to proceed with the most desirable treatment in
the given circumstances, but are unable to do so be-
cause of the rare skin reaction. The present report
serves as a reminder to palliative health care profes-
sionals of the possible danger of a recall reaction if
an insufficient period has passed between radio-
therapy and commencement of a potential recall-
inducing drug.
FIGURE 1 Retrobulbar metastasis, axial, and coronal computed
tomography images with contrast. (A) Axial view of the inferior
orbits demonstrates enhancing abnormal soft tissue posterior and
lateral to the left globe (arrow). (B) Axial view of the upper orbits
demonstrates enhancing abnormal soft tissue in the medial left orbit
inseparable from the medial rectus muscle (arrow). (C) Coronal
view demonstrates abnormal soft tissue in the medial left orbit
inseparable from the medial rectus (arrow) and in the lateral inferior
left orbit inseparable from the inferior rectus and in contact with
the optic nerve (arrowhead).HIRD et al.
55
CURRENT ONCOLOGY—VOLUME 15, NUMBER 1
TABLE I Radiation recall dermatitis (RRD): case summaries
Reference Condition treated Radiation dose Drug leading to RRD a Time to RRD Treatment a
Tan et al., 1959 4 Ewing sarcoma 10 Gy to Dactinomycin Unspecified Unspecified
of the left hip the left knee and (75 mg/kg)
17.5 Gy to 7 days after
the spine completion of RT
D’Angio, 1962 3 Wilms tumour RT to Dactinomycin During administra- Unspecified
the left lung and tion of response-
right paracardiac inducing drug
Von Essen et al., 1963 5 Breast carcinoma 30 Gy 5-Fluorouracil 2 Weeks Unspecified
(15 mg/kg daily
for 4 days)
7 weeks after RT
Sears, 1964 6 Wilms tumour Postsurgical Hydroxyurea 5 Days Unspecified
tumour-bed (60 mg/kg daily)
irradiation 1 month after RT
Wilms tumour Radiation for Hydroxyurea 9 Days Unspecified
pulmonary (60 mg/kg daily)
metastasis 1 month after RT
Rhabdomyosarcoma 30 Gy Hydroxyurea 8 Days Unspecified
of the cervical area (60 mg/kg daily)
47 days after RT
Rhabdomyosarcoma 16 Gy to site Hydroxyurea 16 Days Unspecified
of the cervical area of pulmonary (60 mg/kg daily)
metastasis 7 days after RT
Lampkin, 1969 7 Rhabdomyosarcoma 56.44 Gy to Vinblastine 1 Day Unspecified;
of the right the right face (0.2 mg/kg) same reaction occurred
middle ear 28.32 Gy to 2 months after RT 2 weeks later
the left side
Jaffe et al., 1973 8 Osteogenic sarcoma 26.25 Gy Methotrexate Unspecified Unspecified;
(400 mg/kg) rechallenged 2–3 weeks
24 hours after RT later with no recurrence
Donaldson et al., 1974 9 Fibrosarcoma 59.5 Gy Doxorubicin 7 Days Unspecified;
of the right (Adriamycin: rechallenged at weeks 7
mandible 60 mg/m2) and 15 at the same and
5 weeks after RT reduced doses
with identical reaction
Osteosarcoma 59.5 Gy Doxorubicin 7 Days Unspecified;
of the fibula (Adriamycin: rechallenged after 12 weeks
60 mg/m2) with identical reaction
1 week after RT
Etcubanas and Wilbur, Mandibular Unspecified Doxorubicin Unspecified Unspecified;
1974 10 fibrosarcoma (Adriamycin: after second cycle, a
60 mg/m2) milder skin reaction
4 weeks after RT occurred
Unspecified Unspecified Doxorubicin Unspecified Unspecified;
(Adriamycin: rechallenged twice,
60 mg/m2) with identical reaction
1 week after RT each time
Cassady et al., 1975 11 Lymphoma to the 12 Gy to Doxorubicin Hours Unspecified
right axilla and mantle field (Adriamycin:
supraclavicular fossa 75 mg/m2)
26 days after RT
Osteosarcoma 24 Gy Doxorubicin 7 Days Unspecified
to the left (Adriamycin:
proximal humerus 30 mg/m2 daily for 3 days)
18 days after RT
Rosen et al., 1975 12 Osteogenic 16 Gy Methotrexate 5 Days Unspecified;
sarcoma (200 mg/kg) rechallenged twice
8 weeks after RT with similar reactions
Mayer et al., 1976 13 Metastatic 45 Gy to Doxorubicin 7 Months Unspecified
breast cancer the spine (Adriamycin: (at the time of
80 mg/injection, the 7th injection)
1 injection per month
for 9 months)
given 7 years after RT continuedRADIATION RECALL DERMATITIS: CASE REPORT
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TABLE I continued
Reference Condition treated Radiation dose Drug leading to RRD a Time to RRD Treatment a
Fontana, 1979 14 Small-cell 38 Gy Etoposide 18 Hours Unspecified;
lung cancer (100 mg/m2 on days 1–3) rechallenged 3 weeks later,
7 days after RT resulting in the same reaction
Solberg et al., 1980 15 Acute myelomonocytic 21 Gy Doxorubicin 4 Days Death related to toxicity
leukemia and whole-body (Adriamycin:
leukemia cutis irradiation 35 mg/m2 daily for 3 days)
given 2 days after RT
Weiss et al., 1986 16 Advanced cancers Unspecified Intravenous trimetrexate Unspecified Unspecified
(80 mg/m2 over 24 hours)
every 28 days
Unspecified Intravenous trimetrexate Unspecified Unspecified
(200 mg/m2 over 24 hours)
every 28 days
Unspecified Intravenous trimetrexate Unspecified Unspecified
(200 mg/m2 over 24 hours)
every 28 days
Unspecified Intravenous trimetrexate Unspecified Unspecified
(200 mg/m2 over 24 hours)
every 28 days
Jolivet et al., 1987 17 Lung cancer 40 Gy Trimetrexate Unspecified Unspecified
(2 mg/m2 bolus)
for 9 consecutive days
every 28 days for 2 cycles;
begun 10 months after
completion of RT
Kellie et al., 1987 18 Embryonal 54 Gy Melphalan 24 Hours Unspecified
rhabdomyosarcoma (200 mg/m2)
of the legs 6 weeks after
completion of RT
Nemechek and Corder, Man (age 34) 27 Gy in Intravenous vinblastine 48 Hours Healed by the 5th day
1992 19 with HIV and 15 fractions (10 mg/m2), after chemotherapy
a large Kaposi begun 10 months after RT
sarcoma lesion
on the left foot
Parry, 1992 20 Woman (age 70) Wide local excision Tamoxifen 5 Days Discontinued tamoxifen;
with breast cancer and adjuvant RT (20 mg daily) resolved in 2 weeks;
2 years earlier started 2 years after RT rechallenged at 10 mg daily,
with mild recurrence
Raghavan et al., 1993 21 Recurrent 61.2 Gy to Paclitaxel 5 Days Antibiotics,
breast carcinoma the chest wall; (130 mg/m2 over 24 h), chest wall debridement
65.3 Gy to begun 2 days after RT
the supraclavicular
region
Stelzer et al., 1993 22 AIDS-related Each lesion Intravenous bleomycin 1) 3 Days after In 1) and 2), exacerbated
Kaposi sarcoma randomized to (10 mg/m2) second injection by oral etoposide therapy
1 of 3 possible on a weekly basis 2) 3 Days after started 4 days after
radiation second injection appearance of the skin
fractionation 3) No RRD reaction









Shenkier and Gelman, Advanced 44 Gy Paclitaxel (90 mg/m2) 3 Hours Mild recurrence when
1994, as cited by gastric cancer 7 months after RT paclitaxel given in
7 further cycles
Camidge and Price, 2001 1 Advanced 44 Gy Paclitaxel (90 mg/m2) 6 Hours No recurrence when
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TABLE I continued
Reference Condition treated Radiation dose Drug leading to RRD a Time to RRD Treatment a
Abadir and Liebmalen Woman (age 60) Tumour dose was Simvastatin for 2–3 Days Prednisone and cephalotin
1995 23 with adenocarcinoma 61.2 Gy hypercholesterolemia
of the gallbladder in 34 fractions (20 mg daily),
11 months after RT
Extermann et al., 1995 24 Man (age 55) Tamoxifen Isoniazid 400 mg, plus During 4th week All medications were
with ductal carcinoma (20 mg daily), rifampicin 600 mg, plus of treatment continued, and the reaction
of the right breast plus 48.25 Gy with pyrazinamide 2 mg gradually regressed in the
a 15-Gy boost to treat weeks following
to the tumour bed nasopharyngeal tuberculosis,
4 months after RT
Perez et al., 1995 25 Woman (age 32) 30 Gy to Edatrexate After 3 doses Topical therapy, NSAIDs;
with metastatic the lumbar spine (100 mg/m2 biweekly), (11 days) rechallenged with prednisone
breast cancer begun 6 weeks after RT with mild recurrence
Phillips, 1995, Unknown 25 Gy Paclitaxel (90 mg/m2) 3 Days No recurrence when
as cited by given 27 days after RT paclitaxel given in
Camidge and Price, 2001 1 3 further cycles
Schweitzer et al., 1995 26 Woman (age 61) 43.2 Gy to Paclitaxel Hours Dexamethasone (Decadron:
with metastatic the mediastinum; (175 mg/m2 20 mg),
lung adenocarcinoma 46 Gy to over 3 hours), diphenhydramine (50 mg);
the ribs begun 12 days paclitaxel given with
after RT completion Decadron after 2 weeks
with no recurrence
Bokenmeyer et al., Woman (age 55) 50 Gy to Paclitaxel 5 Days Discontinuation of paclitaxel
1996 27 with breast cancer the breast; (175 mg/m2 over 3 h),
54 Gy to 13 months after RT
the lymph nodes
McCarty et al., 1996 28 Woman (age 51) 50.4 Gy Paclitaxel 4 Days Healing within 10 days;
with invasive lobular in 28 fractions; (200 mg/m2), treatment unspecified
breast carcinoma mild skin erythema 7 days after RT
developed
Yeo et al., 1997 29 Woman (age 51) 30 Gy Docetaxel (100 mg/m2) 4 Days after Dose reduction;
with breast cancer in 10 fractions to on 3-weekly basis and second injection no recurrence of RRD
T10–L4 spine and prior oral dexamethasone
pelvis (Decadron) for 5 days
Bostrom et al., 1999 30 Woman (age 48) with 54 Gy Tamoxifen 2 Months Local steroid cream,
highly differentiated (20 mg/m2 daily) mometasone furoate,
tuboloductal 28 months after RT once daily for 10 days;
breast cancer skin appeared normal 7 weeks
after discontinuing tamoxifen;
after 8 weeks, restarted on
toremifene without recurrence
Wilson et al., 1999 31 Woman (age 46) Unspecified Epirubicin 2 Weeks Surgical debridement and
with breast cancer microvascular free-flap
reconstruction
Camidge & Kunkler, Woman (age 50) 50 Gy Cycle 2 of docetaxel Within 7 days Docetaxel reduced to 75%
2000 32 with breast cancer in 20 fractions (100 mg/m2) with and given 21 days later;
dexamethasone (Decadron: steroids for 7 days
8 mg once daily for 3 days), without recurrence
16 days after end of RT
Castellano et al., 2000 33 Man (age 61) 24 Gy Gemcitabine (1250 mg/m2 8 Days Oral dexamethasone
with stage IV in 8 fractions on days 1, 8, 15 per (second dose) (Decadron) and
NSCLC 28-day cycle) 4 weeks diphenhydramine;
after completion of RT resolved 10 days later;
treatment continued
with other chemotherapies
Giesel et al., 2000 34 Woman with Whole-brain Docetaxel restarted Unspecified Unspecified
breast cancer irradiation: 2 Gy (30 mg/m2 weekly)
for 5 days weekly,
up to 50 Gy
Woman with Whole-brain Docetaxel re-started Unspecified Unspecified
breast cancer irradiation: 2 Gy (100 mg/m2 weekly)
for 5 days weekly,
for up to 50 Gy continuedRADIATION RECALL DERMATITIS: CASE REPORT
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TABLE I continued
Reference Condition treated Radiation dose Drug leading to RRD a Time to RRD Treatment a
Kharfan et al., 2000 35 Woman (age 25) with 30 Gy to Methotrexate (10 mg/m2 7 Days Hydrating emulsions
stage IV lumbar spine and on day +1 after after transplant (treated symptomatically)
nodular sclerosis right proximal bone marrow transplant;
Hodgkin disease femur 15 mg/m2 on
days +3, +6, and +11)
Chan et al., 2001 36 Man (age 50) with 41.4 Gy Oxaliplatin-based 3 Days Aqueous cream and sodium
a sigmoid carcinoma in 23 days chemotherapy fusidate ointment (Fucidin);
(oxaliplatin, plus chemotherapy discontinued
5-fluorouracil, plus and reaction settled after
folinic acid), 2 weeks; 5-fluorouracil plus
resumed 8 days after folinic acid alone resumed
completion on RT without recurrence
Kennedy and McAleer, Malignant melanoma 30 Gy Dacarbazine (800 mg/m2 10 Days Unspecified
2001 37 to the right temple once every 3 weeks),
begun 2 months after RT
Bar-Sela et al., 2001 38 Man (age 65) with RT to mediastinum Gemcitabine Unspecified Unspecified
lung adenocarcinoma and upper lobe
Jeter et al., 2002 39 Woman (age 41) with 30 Gy Gemcitabine 2 Weeks Discontinuation of
breast cancer in 10 fractions to (1000 mg/m2 gemcitabine slowly
lumbar spine every 2 weeks), plus resolved the skin reaction
trastuzumab (Herceptin)
weekly for 4 weeks,
5.5 months after RT
Man (age 79) with 30 Gy Gemcitabine 10 Days Supportive care, alginate
NSCLC in 10 fractions (1000 mg/m2) gel pads, bowel rest
11 days after RT
Woman (age 63) 30 Gy Gemcitabine 3 Days Intravenous steroids for
with metastatic in 10 fractions, (1000 mg/m2), 2 days with minimal
adenocarcinoma plus 25 Gy 3.4 months after RT response
of unknown primary in 2 fractions
(boost)
Morkas et al., 2002 40 Woman (age 39) with 50.4 Gy Docetaxel 10 Days Methylprednisone
infiltrating ductal in 28 fractions, plus (100 mg/m2), plus (80 mg twice daily);
carcinoma 10 Gy to prophylactic docetaxel at 75% induced
tumour bed and dexamethasone a less severe reaction
2 cm surrounding (Decadron)
Ortmann and Hohenberg, Woman (age 56) with 30 Gy Capecitabine 3 Days after Unspecified
2002 41 breast cancer in 10 fractions to (2000 mg twice daily completion
right hip for 14 days) of first course
Piroth et al., 2002 42 Woman (age 40) with 30.9 Gy Docetaxel (30 mg/m2) 14 Days Discontinuation and




Thomas and Stea, Woman (age 29) with Excision, plus Intravenous interferon 6 Days Occlusive dressings with
2002 43 malignant melanoma biweekly alfa-2b wound gel;
of the scalp treatments of 6 Gy, (20×109 IU) resolved in 7 days
totalling 30 Gy administered 5 days
after completion of RT
Ee and Yosipovitch, Woman (age 55) with Photo-recall Chemotherapy Unspecified Unspecified
2003 44 metastatic with taxanes
breast cancer
Jimeno et al., 2003 45 Woman (age 53) with 30 Gy to Pegylated 12 Days Topical steroids
stage IV infiltrating left femur liposomal doxorubicin (betamethasone
ductal carcinoma (40 mg/m2 on day 1 dipropionate); completely
every 28 days), resolved 14 days later
4 weeks after
completion of RT
Keung et al., 2003 46 Woman (age 49) with 50 Gy Arsenic trioxide Day 2 of Arsenic trioxide discontinued,
breast cancer in 25 fractions (0.15 mg/kg daily), week 3 topical triamcinolone/silver
following modified for 5 days each week sulfadiazine cream started
mastectomy for 5 weeks
continuedHIRD et al.
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TABLE I continued
Reference Condition treated Radiation dose Drug leading to RRD a Time to RRD Treatment a
Schwartz et al., 2003 47 Woman (age 37) with Palliative 3 Months later, Unspecified Ciprofloxacin
recurrent ovarian whole-pelvis RT: started on gemcitabine (250 mg twice daily)
adenocarcinoma 45 Gy (800 mg/m2), every other with slight improvement;
in 25 fractions week; reduced to 600 mg/m2 2nd cycle after 2 weeks
because of produced the same reaction
severe neutropenia within 24 hours
Muggia, 2004 48 Woman with RT to Doxorubicin with 2–4 Weeks None;
breast cancer supraclavicular, weekly trastuzumab continued liposomal
internal mammary, doxorubicin
and axillary areas
Singer et al., 2004 49 Woman (age 88) with 50.4 Gy, plus Tamoxifen 3 Months None;
infiltrating 10 Gy (20 mg daily) continued on tamoxifen;
ductal carcinoma to tumour bed completely resolved
3 months later
Borgia et al., 2005 50 Woman (age 63) with 50 Gy Docetaxel 4 Days after Oral methylprednisone
infiltrating over 5 weeks (100 mg/m2), second course resulted in 10-day complete
ductal carcinoma every 3 weeks remission
started 1 week after RT
Kandemir et al., 2005 51 Woman (age 55) with 50 Gy Docetaxel 11 Days None;
breast cancer over 5 weeks (100 mg/m2), plus complete resolution after
oral dexamethasone 6 days; continued docetaxel
(Decadron) for 3 days with no recurrence
Marisavljevic et al., Woman (age 32) with Total dose Gemcitabine (1250 mg/m2 2 Days Skin reaction faded over
2005 52 stage IIB of 60 Gy on days 1, 8, 15), plus 10 days without specific
Hodgkin lymphoma oral dexamethasone treatment; mild recurrence
(Decadron: 8 mg after each gemcitabine
on days 1, 2, 8, 9, 15, 16) administration
more than 2 years after RT
Ash and Videtic, 2006 53 Woman (age 56) with 50 Gy Phentermine Unspecified Prednisone 30 mg daily
infiltrating in 25 fractions, plus 1 year after RT for 2 weeks;
ductal carcinoma additional 10 Gy minimal discolouration
in 5 fractions to after 4 weeks
lumpectomy site
Ayoola and Lee, 2006 54 Woman (age 54) with 64.8 Gy Cefotetan upon 3 Days Cefotetan withdrawn;
lung squamous cell to thorax admission to hospital free of pain in 4 days
carcinoma and mediastinum for cholecystitis
Barlesi et al., 2006 55 Woman (age 75) with Lumpectomy and Pemetrexed (500 mg/m2); 3 Days Steroids
primary lung adjuvant radiation oral prednisone (40 mg) (prednisone 1 mg/kg daily);
adenocarcinoma; to the breast twice daily improvement in 48 hours;
treated for 27 years earlier the day before, the day of, resolution at 2 weeks
breast cancer and the day after
27 years earlier chemotherapy
Fakih, 2006 56 White man (age 52) 1.8 Gy daily Gemcitabine Cycle 5 Withdrawal of gemcitabine
with pancreatic for 50.4 Gy total (1000 mg/m2), for 3 weeks resulted in spontaneous
adenocarcinoma every 4-week-cycle resolution
Kaya et al., 2006 57 Woman (age 41) with UV radiation Methotrexate Unspecified Cold compress;
non-Hodgkin (high dose), plus lesions resolved
lymphoma cytarabine (high dose) within a week
(with hyperpigmentation)
Kundranda and Daw, Woman (age 48) with 50 Gy with Tamoxifen Within 1 week Oral cephalexin did not
2006 58 well-differentiated a boost of 14 Gy (20 mg daily) provide relief;
infiltrating to the tumour bed tamoxifen discontinued,
ductal carcinoma diphenhydramine given;
after 12 weeks, restarted on
tamoxifen with mild
itchiness, but no recurrence
Mizumoto et al., 2006 59 Woman (age 76) with 36 Gy Docetaxel 6 Days Gargle with a local anesthetic
diffuse large in 18 fractions (60 mg/m2) and topical corticosteroids;
B cell lymphoma to the left neck every 3 weeks 80% of docetaxel dose was
of the left neck 1 year after RT given 2 weeks later;
milder recall phenomenon
recurred after 1 week
continuedRADIATION RECALL DERMATITIS: CASE REPORT
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TABLE I continued
Reference Condition treated Radiation dose Drug leading to RRD a Time to RRD Treatment a
Woman (age 60) with 50 Gy Docetaxel Day 6 after Topical corticosteroids;
breast cancer in 20 fractions (30 mg/m2 weekly) second course continued docetaxel therapy
restarted 14 days after RT of chemotherapy for 9 cycles
Putnik et al., 2006 60 Man (age 65) with 64.8 Gy Hypericin 4 Weeks after RT, Symptoms controlled by
squamous cell then again steroid cream,
carcinoma 1 year after RT but disappeared only when
of the epiglottis hypericin was discontinued
Hird et al., 2007 Woman (age 55) with 1) 20 Gy Paclitaxel 2 Days Silver sulphadiazine cream
(present article) metastatic breast in 5 fractions to (175 mg/m2) and and hydrocortisone eardrops;
adenocarcinoma the thoracic spine gemcitabine discolouration still apparent
(October 2006) (1000 mg/m2) after 8 weeks;
2) Whole-brain administered 1.5 weeks started on CEF with concurrent
radiation: 20 Gy after completion of dexamethasone (Decadron)
in 5 fractions whole-brain radiation without recurrence
(November 2006)
a Holders of named pharmaceutical trademarks: Adriamycin: Pharmacia, Kalamazoo, MI, U.S.A.; Decadron: Merck and Co., Whitehouse
Station, NJ, U.S.A.; Fucidin: Leo Pharma, Ballerup, Denmark; Herceptin: Genentech, San Francisco, CA, U.S.A.
RT = radiotherapy; NSAIDs = nonsteroidal anti-inflammatory drugs; NSCLC = non-small-cell lung cancer; UV = ultraviolet; CEF = cyclophospha-
mide, epirubicin, 5-fluorouracil.
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